Patients older than 65 years who develop acoustic neuromas have the same signs and symptoms as younger patients. Age limits beyond which surgery for acoustic neuroma is currently not recomm ended are unreasonable. Untreated vertigo in olde r patients fre quently results in f alls that can cause fr acture of the f emur and significant morbidity and mortal ity. Surgical removal of acoustic neuromas in patients olde r than 65 produces results that are as good as those seen in youngerpatients. The patient' s general medical condition, life expectancy, and fac tors other than chronological age should be considered when surgery is being contemplated. Acoustic neuroma surgery fo r the older patient can provide gratifying results and should not be withheld strictly on the bas is ofage.
have been sugges ted.!" even tho ugh it has been show n that aco ustic neuroma surge ry in ger iatric patient s can be benefici al-" and that a patient ' s ge neral medic al co nditio n, Iife ex pec tancy, and facto rs othe r than chro nolog ical age sho uld be co nsidere d when surge ry for acou stic neu rom a is being co ntemplated.
Neurotologic examina tion
Regardless ofwhich treatment is ultimately recommended, the physician must esta blish an acc ura te diag nos is for the pat ient who complains of tinni tus, hear ing loss, vertigo, ataxia, headache, or facia l numbness .' Each patient sho uld undergo a complete neurotologic examinat ion, including audiography for air and bo ne co nduction and speech discri minat ion, determinations of auditory evoked po tential (AEP), the Short Incre men t Se nsitivity Index (S ISI) test, the Bekesy sweep frequ ency, and impeda nce audio metry . At a minimum, ves tibular tests should includ e e lectro nys tag mog raphy or maneu vers to induce spo ntaneou s positional and ca loric nystagmu s. When available, the test for sinuso idal harm onic acce leration and the vestib ular autorotation test (VAT) can be helpful. Gad olinium -enh anc ed magn eti c reson ance imaging (MRI) sho uld be perform ed to study the ce rebellopontine ang le, the bra instem, and the entire brain. These tests will identi fy the presence of an aco ustic neuroma and provide infor mat ion on the size of the tu mor and the physiologic function of invo lved nerves so that an appropriate surg ica l tec hniq ue and approach ca n be se lecte d. It is desirabl e to proceed with other tes ts, such as a 5-hour glucose tolerance test and lipid phenotyping, to estab lish the ca use of the symptoms.
Th ere are many types of vertigo in the elderly that are not caused by aco ustic neurom a. Ischemia in the ea r and brai n caused by atherosclerosis is more com mon in the e lde rly. Degenerative cha nges of the maculae and cristae of the equi librial labyrin th occur more ofte n duri ng the adva ncing yea rs, possibl y as a resul t of inadeq uate nut rition . Pos itiona l vertigo ca n be ca used by an atherosc lerotic obstruction in one verte bra l artery or in one of the ca rotid arteri es. For these co nditions, Doppl er studies, magnet ic resona nce angiography , or vertebra l and ca rotid ang iography might be indicated . PULEC . Orthostatic hypotension might require si mple co unse lmg so that the patient knows to allow ade qua te tim e for the vas~u l r system to respo nd to postu ral cha nges. In the genatnc population , one must not forzet to con sid er ot her conditions, such as chronic otitis Ĩ edi a otosclerosis I ? m us tumors, syp hilis, allergic endo lymp'hatic hyd rop s:
IdIopathic Meniere's disease, etc.
Treatment
As is the case in younoer ace groups a variet y of opti on s
IS aVaIlable for the treatm ent of aco us tic neuroma in g erĩt ri c patient s, depending on their general condition; the~I z e of the tumor; the tumor's nerv e of origin (inferior vestibulanerve , superior vestibular nerve, or cochlear nerve); the physiolooic functi on rernaininz in the sur-
structures; the desires of the patient; and thẽ raI nI n g , ability, and skill of the surgeon. These opti on s Include observation only (no treatm ent) and surg ica l approac hes to save hearin g by the middle crani al foss a approach or suboccipital approac h, the translab yrinthine approach, translabyrinthin e VIIIth nerve sectio n to alleviate symptoms only, and gamma kni fe surg ery . Observation with peri odic ima ai nz is a reasonable
op tion for patients who have lost all hea ring, whose tumors do not tou ch the brainstem and wh o ha ve no tinnitus or ver tigo. Tum ors 2 Col in diame ter and lar s er will pre. ss on the brain stem , and surg ica l rem oval sho: ld be co nsIdered. Pati ent s with intercanalicular tum or s who have useful hearing sho uld be give n the option of hearing preser vation by the middl e cranial fossa or subocc ipital appr?ac h without del ay. In my expe rience, the middle c r an~al fossa approach is the most reliable way to obtain surgica l removal and to pre serve hearing. Even for small Intrac analicular tumors originatin 0 from the inferior vestibul ar nerve, hearing can se l do~be saved. The best oppo rtunity to pre serv e hearing is in pati ent s who ha ve sma ll superior vestibular nerve neurom as (small tum or , goo d hearing, but delayed AEP latency or poor morphology and abse nt calori c reac tion).
Middle cranial fo ssa approach. Th e middle cranial fossa approach to th e inte rnal audi tory ca na l a nd er eb el l op onti n e ang le is idea l fo r pat ient s wi th Intracanalicular tum ors of the supe rior ves tibular ner ve and for those in who m we wis h to preser ve hearin g. T his app roach spa res the cochl ea and labyrinth so that the are a ca n be explored witho ut damaze to the hearins and the vestibular sys te ms . Sh ould the ; ath ology be of7he facial er ve or ano ther type of neopl asm , the functio n o f the ear IS left undi sturbed. On e disad vant aze of the middle cranial fossa approach is that the procedure for tum or removal can seldom be don e in less than 2 hours.
. Retrosigmoid approach. Th e retrosigmoid approach, In contrast to the earli er suboccipital approach, has so mewhat subtle differences. In the suboccipital approach, a 430 larger cra niec to my is usu all y performed , with the sigmoi d sinus be ing the anter ior ex tent of the craniec to my. With the re tros igmo id approac h, bo ne is rem oved fro m aro und the sig mo id sinus, and the sig moi d sin us is retracted anter iorly to minimize ce rebe llar retr acti on and to provide an ade quate view of the cerebe llo po ntine ang le . As with the middle crani al fossa approach, the virtue of the retrosigm oid approach is that the lab yrinth and cochlea are not dam aged , thereb y providing an opportunity to save hearing. The major advantage of the retrosigmoid approac h is for the removal ofla rge r tum or s. It is valuable fo r the removal of 1.5-to 2-cm tumors on an " only hearing ear." The procedure has tw o major disadvantages: I) the complete removal of all tumor at the lateral end of the int ernal auditory canal is not always possible and 2) disabling severe headache lastin g for as lon g as I ye ar aft er surge ry frequently fo llo ws a retrosigmoid or suboccipital approach. 10 Translabyrinthine approach. Th e most versatile of the surg ica l approa ches is the tran slabyrinthine approach , whic h is useful fo r the re moval of most aco ustic neu romas. Thi s proc edure is es pec ially de sir ab le fo r ger iatric pa tie nts because of the low morbidity it confers. Th e tran slabyrinthine approach is an excelle nt meth od for rem ovin g tum ors of all sizes, es pec ially the very largest (4 to 5 ern). Wh en the techniqu e is per formed by an experience d surgeon, operating tim e can be ke pt to a minimum. M oreover , the procedure can be don e under loc al anes thesia when necessary. Th e skin incision is sma ll, so ft tissue and mu scle are minimally invol ved , and the ch anc es of bleeding, postoperative ede ma, and complications are slig ht. Ho spitalization usually lasts no longer than 4 day s.
Gamma knife surgery. Radiosurgery, introduced in 1951 by Swedish neurosurgeon Lar s Leksell, MD , refers to a technique that utilizes coba lt 60 radiation, a stereotactic head frame, and computer dir ect ion to rad iologically destroy tissue in a prec ise wa y. Mod ern gam ma knife equipme nt has significantly imp ro ved results. Th e proc edure invol ves the pl acem ent of a stereo tac tic frame in the operating room . Th e fram e is fixed to the skull firml y by several point ed sc rews, whic h are placed throu gh sma ll incision s in the sca lp. The head is then surrounde d with a large metal he lme t co nta ining multi ple ope nings that can be oc cl ude d or left ope n to allow the co ba lt beam s to pass throu gh . By ca refully ai ming and by determining tim e of ex pos ure, one can control tissue dam age to reasonably accurate tolerances. Hosp itali zation is often for only I night , and the procedure is don e wit ho ut ge ne ra l anesth esia. The cost to the pati ent is approx ima tely the same as for surg ica l remov al, altho ug h in some areas gamma knife tre atm ent is significa ntly more ex pe ns ive.
Despite the app arent init ial minimal morbidity ofgamma knife treatment vs. surgery , significant complications have been reported, including nausea and vomiting, faci al
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PULMICORTTURBUHALER is not a bronchodilator and is not indicated for rapid relief ofbronchospasm or other acute episodes ofasthma.
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Allhough patienls inclinical trials have received PULMICORTTURBUHALERon acontinuous basisforperiods of 1 to 2 years, the long-term local and systemic effects of PULMICORT TURBUHALER in human subjects are not complelely known. Inparticular, the enects resulling from chronicuseof PULMICORT TURBUHALER on developmental or immunological processes inthe mouth, pharynx, trachea, and lungare unknown.
Inclinical trials with PULMICORTTURBUHALER, localized infections with Candida albicans occurred inthe mouth and pharynx insome patients. II oropharyngeal candidiasis develops, it shoul d be treated with appropriatetocal or systemic (i.e., oral) antilungal therapy while still continuing wilh PULMICORT TURBUHALERtherapy, but at times therapy wi thPULMICORT TURBUHALERmay need tobe temporarily interruptedunder close medical supervision.
Inhatedcorticosteroids should be usedwith caution, ifatall, inpatients wilhactive orquiescent tuberculosis infection 01 the respiratory tracl. untreated systemic fungal , bacterial, viral orparasitic inf ections; orocular herpes simplex.
Rare instancesofglaucoma, increased intraocular pressure, and cataracts have been reportedfollowing Iheinhaled administration 01 corticosteroids. Drug Interactions: Inclinical sludies, concurrent administ ration ofbudesonide and other drugs commonlyused inthe Ireatmenl ofasthma has nol resulled inan increasedfrequency ofadverse events. Ketoconazole, apotent inhibitor ofcytochrome P450 3A, may increaseplasma levelsofbudesonide during concomitant dosing. Theclinical signiticance of concomitant administration 01 ketoconazole with PULMICORT TURBUHALER is nol known, but caution may be warranted. Carcinogenesis, Mutagenesis, Impoirment of F er~l i t y : Long-fermstudies were conducted inmiceand rats using oral administration toevaluate the carcinogenic potential ofbudesonide.
There was no evidence 01 acarcinogenic effect when budesonide was administered orally for91weeks tomice at Sprague-Dawley and Fischer rats. These studies did not demonstrate an increased gl ioma incidence in budesonidetreated animals as compared with concurrent controls or reference corticosteroid-treated groups (prednisolone and triamcinolone acetonide). Compared with concurrent controls, a statistically significant increase in the inci dence of hepatocellular lumors was observed inall three steroid groups (budesonide, prednisolone, triamcinolone acetonide) in these studies. Pregnancy: Teratogenic Effect s: Pregnancy Category C: As with other glucocorticoids, budesonide produced fetal loss, decreased pup we.ight and skeletal abnormalilies at subcutaneous doses 01 25 !TIcglkg/day in rabbils (approximately 'I,the maximum recommended dallyInhala1l0n dose Inadults on amcg/m' baSIS) and 500 in rats (approximately 3 times Ihe maximum recommended daily inhalation dose in adults ani amql/m ' ; basis) No teratogenic orembryocidal effects were observed in rats when budesonide was administer halation at doses up to250 mcglkg/day (approximately 2times the maximum recommended daily inhalation dose inadults on a mcg/m' basis).
Thereare no adequate andwell-controlled studies inpregnant women. Budesonide should be usedduring pregnancy only il the poieotial benefit justifies the potential risk tothe letus.
Experience with oral corticosteroids si nce their inlroduction in pharmacologic as opposed to physiologic doses suggests that rodentsare more prone toteratogenic eflects Irom corticosteroids than humans. Nonteratogenic Eff ecls: Hypoadrenalism may occur in infants bornofmothers receiving corticosteroids during pregnancy. Such inlanfsshouldbe carefully observed. Nursing Mothers: Corticosteroids are secreted in human milk. Because 01 the potential loradverse reactions in nursing Infants Irom any corticosteroid, adecision should be made whether toaiscontinue nursing ordiscontinue the drug, taking into account the importance ofthe drug tothe mother. Actual data forbudesonideare lacking. Pediatric Use: Safety and eflectiveness 01 PULMICORTTURBUHALERinpediatricpatents below 6years ofage have nol been established.
Inpediatric asthma patients the Irequency 01 adverse events observed with PULMICDRT TURBUHALERwas similar between the 6-to12-year age group (N=172) compared withthe 13-to17-year age group (N=124).
Oral corticosteroids have been shown tocause growthsuppressioninpediatric and adolescent patients, particularly with higher doses over extended periods. II a pediatric oradolescent patient on any corticosteroid appears tohave growth suppression, Ihe possibility that they are particularly sensitive to this effect 01 corticosteroids should be considered (see PRECAUTIONS). The table above Includes all events (whether considerec drug-related ornon drug-related bythe investigators) that occurred atarateof;,3% inanyone PULMICORTTURBUHALERgroup and were more common than inthe placebo group.Inconsidering thesedata, the increasedaverage duration ofexposureforPULMICORTTURBUHALER patients shouldbe taken into account.
The following other adverse events occurred in these clinical trials using PULMICORT TURBUHALERwith an incidenceof1to3% and weremorecommononPULMICORT TURBUHALER thanonplacebo.
• • SpecialSenses: taste perversion In a 20-week trial in adull asthmatics who previously required orat corticosteroids, the eflects of PULMICORT TURBUHALER 400 mcg twice daily (N=53) and BOO mcg twice daily (N=53) werecompared wilh placebo (N=53) onthe frequency 01 reported adverse events. Adverse events, whether considered dr or non drug-related bythe investigators, reported in more than fivepatients in the PULMICORT TURBUH Pand which occurred more frequently with PULMICORT TURBUHALER than placebo are shown below ORT TURBUHALER and % placebo). Inconsidering these data, the increased average duration of exposure lor PULMICORT TURBUHALER patients (7B days for PULMI CORTTURBUHALERvs, 41days for ptacebo) shouldbe takeninto account. T he true place for the gamma knife in the treatment of acoustic neuro ma has yet to be dete rmined . At the prese nt time, the gam ma knife is an alternative therapy for the treatment of aco ustic neuroma for patients whose medical cond ition makes the administration of a general anesthetic or a surgical proce dure unsafe, or for patients who are excess ively fearful of having surgical tumo r removal.
Case reports
Case 1: Healthy septuag enarian. A 76-year-old white woman was see n on Jul y 18, 1995, some 6 weeks after she was involved in an auto mobile accident and sustained a whiplash inj ury and left hea ring loss. She experienced tinnitus in the left ear for2 days after the acci dent. She also stated that 2 years earlier, she had experienced vertigo, which lasted for 2 days . The woma n was in good general health. She was a retired schoo l teacher who still worked active ly tutoring student s, and she led a busy and energetic life. Physical examination of the ears, nose, and throat was normal, except for a left sensorineural hearing loss at an average of 40 dB and 20% speech discrimination (figure I). The patie nt's SISI scores were low bila terally. She had a type IV Bekesy trac ing on the left side. Electron ystagmography revea led a second-degree right-beating spontaneo us nystagmus and reduced vestib ular respon se on the left to caloric stim ulation (fig ure 2 ). VAT showed a unil ateral reduced vestib ular response. The MRI with gadolinium enhancement revealed a 1.2-cm left acou stic neuroma (fig ure 3 ). Her genera l medical examination revealed that she was in exce llent health.
The patient underwent surge ry on Oct. 25, 1995, a little more than 3 month s after her initial visit. After a general anesthetic was administered, a tran slabyrinth ine approach was performed to totally remove the acoustic neuroma, which arose from the infer ior vestibul ar nerve . An autograft of abdominal fat was used to fill the mastoid and activi ty, she had no tinn itus, and her face was norm al. She reported only incon seq uential postural ver tigo. Comment. Thi s vivacious woman deve loped an aco ustic neur oma and had it rem oved surg ically at age 77. She has continued her active lifestyle and remains of value to soc iety by tutorin g studen ts. The short hospit ali zation and minimal morbidity allowed her to return to full activity shor tly after surgery.
Case 2: Preservation ofhearing in a sex agenarian. A 67-yea r-o ld whi te woman was seen on Oct. II , 1995, with a co mplaint of left hearing loss and tinnitus of 6 weeks' duration follow ing a co ld and sore thro at. Audiography revealed a left sensori ne ural hearing loss, wit h an ave rage of 35 dB for pure tones and 98% speec h discrimin ation (fig ure 5 ). The right ear was normal, and her SISI scores were normal bilaterally. Impedance audio metry was within norm al limit s, and the Bekesy audi ogram was type II on B.B.
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Ear SRT petrous apex . Her postoperative co urse was uneventful, and she was disch arged on the fourth day. Her facial nerve functioned normally (fig ure 4 ). She pro mptly returned to full activity. The wo man still experience d some mild tinnitus (its intensity was less than the preo perative level) and mild positional vertigo. When she was last see n on Jul y 2 1, 1997, 2 years after her first visit, she remai ned at full the left side. Electrony stagmography was within normal limit s bilat erally ( figure 6 ). Th e VAT was ju st slightly abnormal. Brainstem audio metry reve aled flat tracin gs without waves in the left ear. A presumptive diagno sis of left aco ustic neur oma involving the inferior vestibular nerve was made. This diagnosis was co nfirmed by a gadolinium-enha nced MRI , which dem onstrated an 8mm lesion in the left intern al auditory canal ( figure 7) .
PB Max
Th e patient underwent surge ry on Feb. 13, 1996 , about 4 mo nths after her initial visit; the acoustic neurom a was still 8 mm in diameter ( figure 8 ). General anesthesi a was administered, and a middl e cranial fossa appro ach was used to remove the aco ustic neur oma. The facia l and coc hlear nerves were preser ved. Postoperative facial motion was norm al (figure 9). Sh e was discharge d from the hospit al on the fifth postoperati ve day.
A persistent cerebro spinal fluid (CSF) otorhinorrhea requ ired reoperation to seal muscle cells that had been opened bet ween the petrou s apex and the internal auditory canal. The patient has returned to full activity, and when see n on Ap ril 17, 1996, she had no vertigo or tinnitu s, and the hearin g in her left ear was imp roving. Facial functi on has remained completely normal. A postop erative audi ogram on Jul y 18, 1996, showed useful hearin g ( figure 10 ). Brainstem audiometry dem onstrated a return of normal morph ology with shortening of the Vth wave latenc y.
Comment. Th is case demon strates an ideal result for any patient with acoustic neuroma. Facia l functi on is normal. Th e patient is at full acti vity and has useful hearin g with out tinnitus. Remo val of her superior vestibular ner ve and the rare occurrence of CSF otorhinorrhea in a middl e fossa case has caused her no significant longterm morbid ity. Thi s is the only middl e foss a case that has required seco ndar y clo sure in my series." her seve re sympto ms of instability and her seve re respiratory problems, left tran slabyrin thine VIIIth nerve sec tion or remova l of the tumor under a local anesthetic was plann ed. On Jan. 30, 1996, with oxygen administered by a mask and monit ored by an anesthesiologist, a left translabyrinth ine removal of an 8-mm aco ustic neur oma involving the inferi or vestibular nerve was performed. Th e tumor was totall y removed. Homograft fat was used roma on Jan . 8, 1996 . She had had progressive hearing loss on the left with tinnitu s for 4 month s. Her chief complaint, however, was disabling verti go for the previous 2 year s. She said that she could not walk straight and that she would run into walls. Hercompl aint was so seve re that she felt disabl ed. Her history includ ed two strokes 7 year s earlier, with temp orary speec h impai rment. She had severe emphyse ma and routinely used oxygen at night. At the time of my ex am ination, she was using nasal oxygen from a portable tank . She smoked approx imately 30 cig arettes per day and was troubled with seve re emphysema. Aside from the severe respir atory difficulty, her physical examination was normal except for hearing and vestibular loss in the left ear. Speech discrim inati on was 16% with a pure-tone average of 68 dB on the left side ( figure  11 ). Otoacou stic emiss ions testin g was cons istent with the hearin g lo ss on the audiogra m. Elec tro nystagmography rev ea led a right-b eating spontaneo us nystagmus and redu ced vestibular response in the left ear to caloric stimulation ( figure 12) .
The patient was unable to perform the VAT accu rately. MRI with gadolinium enhancement revealed an 8-mm intrac analicular acou stic neuroma ( figure 13 ). Because of 1-888-343-MEDS Fax: (423) 481-0921 E-mail: Customerser vice @allmeds .com http:/www.allmed s .com/ OtoMeds'" is a member of the AllMeds'" integrated CPR products.
OtoMeds<D is the first Computerized Patient Records system written specifically for otolaryngology. Designed by a practicing otolaryn gologist, Ototvieds" saves you time.. .lots of time. No dictation , no hand writing notes. OtoMeds©is designed to fit your office immediatel y, so you reap the rewards the very first time you use it. OtoMeds <D takes care oj the records. You take care oj the patients. to obliterate themastoid and petrous apex . A conversation was carried out with the patien t throughout the procedure, and she repo rted no pain, eve n during the dissection of the tumor from the facia l nerve . Total operating time, incl uding injection of anes thetic arid placement of the bandage, was I hour and 40 minutes. Facial function followi ng surgery was co mpletely norm al for I week , after which paralysis developed. She was hosp italized for a total of 6 days , primarily as a precaution because of her seve re emp hysema. Fac ial function began to recover within 1 week and was comp letely normal when exa mined 10 weeks later ( figure 14) . At that time, she had goo d balance , no tinnitus, and norma l facia l motion, and she was at full activity .
Contact us today
Comment. T his is the only patient with aco ustic neu-roma upon whom I have performed a tran slabyrinthine approach using a local anest hetic. My plan was to do a co mplete VlIIth ner ve section to eliminate the symptoms of vertigo and tin nitus. The procedure we nt so we ll that it seemed reaso nable to totally remove the sma ll tumor. As with all surge ry, procedures sho uld be perfected so that opera ting time is reaso nably short and the techn ique produ ces minim al morbidity. With translabyr inthine removal of a sma ll tumor, the incision ca n be smaller, the bony removal and exposure of the cere bellopontine angle ca n be made much smaller, and, espec ially for the geriatric patient , closure ca n be acco mplished using homograft fat, thereby avoidin g the need and added morbidity of creati ng a donor site in the abdo men. In order to perform surgery under a local anesthetic, it is important that the patient understand ahea d of time the need to coo perate, and the surge ry should take less than 2 hour s to perform.
Case 4: The gam ma knife alternativ e. A 70-year-old white wo man act ive in soc ial and char ity wo rk firs t noted that she could not hear a friend sitting to her left during din ner in Septemb er 1986. The followi ng day, she consulted her otolary ngologist, who immediate ly reco mmen ded an MR I, which demonstrated a left aco ustic neur oma. She was referred to a neur otologist, who was unable to see her pro mptly. She co nsulted a university otolaryngology de part men t chief who, she said, "scared me half to death" and then told her that she did not need surgery. She subse que ntly developed severe tinnitu s in the left ear and saw an otolog ist in ano ther city, who, with a neurosurgeon, performed a suboccipital approa ch opera tion for the rem oval of the left aco ustic neur oma on Jun e 8, 1987 . Hearing was preserved, although the patient had increasingly severe left tinnitus. Th e patient complained that she had a very long postoperati ve course and multiple co mplications from the surgery . She took increas ingly larger doses of tem azepam and sought co nsultation with three different psychi atrists. She had pro- longed severe headaches and a fee ling that her head was "very big ."
InApril 1989, her hearing deteriorated on the left. She consulted her surgeon, who ordered an MRI, which he inte rpreted as scar tissue and told her there was not too much to be worried about. The following week, she obtained a letter from the surgeon stating that there might be recurrent disease. The otologist told her that he wo uld speak to a neurosurgeon about it. After several weeks had passed, she called him back and was told that he had forgotten to speak to the neurosurgeon. She sought help from another neurosurgeon, who confirmed that a tumor was present. She was referred by him to a neurosurgeon in another part of the country for consideration of gamma knife therapy. This physician recommended that gamma knife therapy not be performed.
In March 1990 , the woman noticed left-sided fac ial weakness, which resolved spontaneously in 6 weeks . The patient consulted with other pat ients who had undergone gamma knife therapy, and she talked with the president of the Acoustic Neuroma Society. Ultimately, she consulted a physician at Good Samaritan Hospital in Los Angeles, who performed the gamma knife treatment on Feb. 4, 1991 (figures 15, 16) . Several mo nths following gamma knife treatment, her tinnitus had completely subsided and her facial function has remained normal. The 1.7-cm residual left acoustic neuroma of Feb. 4, 199 1 ( figure 16 ), showed regression by MRI with gadolini um enhancement on Feb . 2 I, 1995 (figure 17) .
Comment. This case illustrates an unsatisfactory resu lt and incomplete removal by the suboccipital approach, which was performed by an oto laryngologist and neurosurgeon. The recurrence of symptoms, the morbidity of the surgical procedure, and the increasing size of an incomplete ly removed tumor understandably led to the patient's disillusionment with surgery. She therefore sought alternative treatment with the gamma knife. 
PULEC
The exact place for the use of gamma knife surgery in the treatment of acoustic neuroma is controversial at this time . As is the case in surgical removal, the results, success, morbidity, and mortality vary greatly among different operators. Neither approach always offers perfect results or is free of complications. Only time will answer the many questions concerning the true place for each technique. At this time , however, it seems clear that at least a few patients with acoustic neuroma are candidates for the gamma knife and fall into two categories. The first is a patient whose tumor is enlarging and who is in poor general health, which would prevent the safe administration of a general anesthetic. When the risk of surgery is unacceptable for that reason, use of the alternative of a gamma knife treatment seems reasonable.
The second indication is in the otherwise healthy patient with an enlarging tumor who has an unusual fear of surgery. Unfortunately, those patients are usually not informed of the risks of gamma knife, which include possible failure to control tumor growth, transverse myelitis, facial paralysis, vertigo, and radiation-induced sensory hearing loss .
Discussion
Management of the geriatric patient with acoustic neuroma is no different from that for younger patients. The signs and symptoms and the indications for the specific type of treatment are identical. Patients of any age who develop tinnitus, hearing loss, or vertigo should expect to have prompt diagnostic tests performed by their physicians to exclude the presence of acoustic neuroma and to establish the proper diagnosis. Every patient with one or more of these symptoms should have a complete neurotologic examination, including an audiogram for air and bone conduction and speech discrimination, AEP, SISI test , Bekesy test, and impedance audiometry. Vestibular tests include alternate bilateral bithermal caloric testing with electronystagmography. MRI with gadolinium enhancement of the entire brain and cerebellopontine angle should be performed. Should no tumor be found, other specific examinations should be performed to make the correct diagnosis.
For practical purposes, the treatment of acoustic neuroma is no different for geriatric patients than for their younger counterparts. If anything, a prompt, expeditious examination and early institution of treatment is more important in geriatric patients because they are at greater risk of serious complications in the event of a fall. It is extremely important that physicians suppress any urge to neglect doing a thorough examination to establish an accurate diagnosis in the elderly. Most older patients consider life to be even more dear than they did in their youth , and they seek to protect their health with great 440 ardor. Studies have repeatedly demonstrated that patients who reach an advanced age have already shown that they have better-than-average health and can withstand adversity. Surgery in the centenarian is surprisingly successful and should not be withheld when indicated.":"
A prolonged surgical procedure inevitably carries greater morbidity, especially in the older patient. Acoustic neuroma surgery should be performed quickly and efficiently, seldom exceeding 3 hours, even in the most difficult case. The translabyrinthine approach can be performed the most quickly and carries the least morbidity . Temporary facial palsy is best treated with a palpebral spring.'? The procedure can be performed in selected cases under a local anesthetic, as demonstrated in case 3. Treatment to eliminate vertigo in the elderly is extremely important, because falls often result in hip fracture, with subsequent morbidity and death.
The gamma knife is an alternative for patients who are unwilling to undergo surgical removal and for those whose medical condition would make such an effort unwise. The long-term results of surgery with the gamma knife are unknown. Generally, the gamma knife is used to treat acoustic neuromas without a tissue diagnosis. I have seen a case treated by gamma knife that I did not believe was an acoustic neuroma, based on all available tests . In fact , my diagnosis was edema of the nerves within the auditory canal in a young woman. It is for such a case that the middle cranial fossa approach .is ideal to confirm a diagnosis, as well as to preserve function and structures.
Conclusions
Patients over 65 years of age with acoustic neuroma should be treated no differently than younger patients. Indications for surgical removal are based on the patient's symptoms, life expectancy, and ability to safely undergo a surgical procedure. As with all acoustic neuroma surgery , the procedure should be done precisely and effectively to minimize morbidity. Chronological age should receive minimal consideration. The symptoms of vertigo and instability require prompt treatment to avoid a fall , which could result in a broken hip and ultimately death.
A case of translabyrinthine removal of acoustic neuroma under local anesthesia was first reported in this communication. The use of gamma knife treatment is an alternative for patients with acoustic neuroma in poor medical condition or who do not wish to have surgical removal.
INDICATIONS AND USAGE
For thetreatment 01superficial bacterial inlections 01the external audi torycanal, caused by organisms suscept ible to the action of the antibiotics; and lor the treatment 01 infections 01 mastoidect omy and fenestration cavit ies, caused by organismssuscept ible tothe antibiotics.
CO NTRAtNDlCATIONS
This product is contrai ndicated in those individuals who have shown hypersensitivity to any ot its components, and in herpes simplex, vaccinia, and varicella.
WARNIN GS
As wi thother antibiotic preparations, prolonged treatment may result in overgrowth 01 nonsusceptible organisms and lungi. If theinlection is notimproved after one week, cultures and susceptibilitytests snouid be repeated to verity the identity oftheorganism and todetermine whether therapyshould bechanged. Patients who preter to warm the medication belore using should be cautioned against heating the suspension above bodytemperature, in order to avoid loss of potency.
PRECAUTIONS
General II sensitization or irritationoccurs, medicationshouldbediscontinued promptly. Thisdrug shouldbeusedwithcare incases 01 perloratedeardrum andinlongstandingcases 01chronic olitismedia becauseofthe possibility of ototoxici tycaused by neomycin. Treatment shouldnot becontinuedfor longer thantendays. Allergic cross-reactionsmayoccurwhichcouldprevent theuseof anyorall01thefollowingantibiot ics forthetreatment 01 fut ure infections: kanamycin, paromomycin,streptomycin, and possiblygentamicin.
ADVERSEREACTIONS
Neomycin is a not uncommon cutaneous sensitizer. There are articles in the current literature that indicate an increase inthe prevalence ofpersons sensitive toneomycin.
DOSAGEAN D ADMINISTRATION
Theexternal auditory canal should bethoroughlycleansed and dried withasterilecolton applicator. Whenusing the calibrateddropper: For adults, 5 drops 01 the suspension shoul d be instilled into the allected ear 3 or 4 times daily. For pediatricpatients, 4drops are suggested becauseofthesmaller capacityoftheear canal. Thisdosagecorrel atestothe 4drops (loradulls)and 3drops (lor pediat ricpati ents) recommendedwhen using the dropper-boillecontainer lorthis product Thepatient shouldliewiththeaflect edear upward andthenthedropsshouldbeinstilled. Thisposition should be maintained lor 5 minul es to facilitatepenetration otthe drops int o the ear canal. Repeal , iI necessary, for the opposite ear. Ifpref erred, acollonwickmay be inserted into the canal and then thecollon may be saturated with the suspension. Thiswick shouldbe keptmoist byadding turther solutionevery 4 hours. Thewickshould be replaced atleast once every 24hours.
HOW SUPPLIED
Cortisporin' -TC Otic Suspension issupplied as: NDC61570-090- 10 10-mL bonle with dropper EachmLcontains: Colist insUllate equivalent to3mgofcolist inbase activily, Neomycinsullate equivatent to 3.3 mg neomycin base aclivity, Hydrocortisone acetate 10mg (1%), Thonzonium bromide 0.5 mg (0.05%), and Polysorbate 80 in an aqueous vehicle bufl ered with acetic acid and sodi um acetate. Thimerosat (mercuryderivative)0.002%addedas apreservative. Asterilized dropper -capassembly lor useon theboule 01suspension isincluded inthepackage. Shake well before using. Store at controlledroom temperature15' ·30' C(59"86 ' F). Stabl e for 18months at room temperature; protonged exposure to higher tem peratures should be avoided. Rxonly. 
